Opendata, web and dolomites

TUDCA-ALS SIGNED

Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TUDCA-ALS project word cloud

Explore the words cloud of the TUDCA-ALS project. It provides you a very rough idea of what is the project "TUDCA-ALS" about.

modestly    cord    treatment    diagnosis    alsaq    latter    life    sporadic    neurofilament    biomarkers    respiratory    iib    als    corresponding    weakness    sclerosis    population    die    function    tauroursodeoxycholic    atrophy    motor    rating    positively    treatments    time    csf    disorder    tudca    obtain    muscle    primary    prevalence    endpoints    grounded    benefits    neurons    revised    brain    secondary    majority    trial    therapeutic    lateral    proof    ing    ambition    ventilation    invasive    successful    neurodegenerative    spinal    expert    progressive    quality    involvement    muscles    administration    rare    biomarker    serum    international    mrc    tracheostomy    randomized    perform    efforts    acid    force    amyotrophic    brainstem    levels    voluntary    therapy    mmp    riluzole    survival    functional    measured    efficacy    cooperation    questionnaire    data    forced    vital    expression    clinical    patients    death    patient    eq    correlated    deterioration    cognitive    safety    endpoint    combining    skeletal    capacity    performed    5d    prove   

Project "TUDCA-ALS" data sheet

The following table provides information about the project.

Coordinator
HUMANITAS MIRASOLE SPA 

Organization address
address: VIA MANZONI 56
city: ROZZANO (MI)
postcode: 20100
website: www.humanitas.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.tudca.eu/
 Total cost 5˙596˙928 €
 EC max contribution 5˙596˙928 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2017-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HUMANITAS MIRASOLE SPA IT (ROZZANO (MI)) coordinator 1˙526˙994.00
2    THE UNIVERSITY OF SHEFFIELD UK (SHEFFIELD) participant 731˙906.00
3    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) participant 689˙197.00
4    UNIVERSITAET ULM DE (ULM) participant 647˙125.00
5    BRUSCHETTINI SRL IT (GENOVA) participant 516˙868.00
6    CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS FR (TOURS CEDEX 9) participant 490˙906.00
7    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 352˙281.00
8    THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN IE (DUBLIN) participant 351˙086.00
9    ISTITUTO SUPERIORE DI SANITA IT (ROMA) participant 239˙375.00
10    MOTOR NEURONE DISEASE ASSOCIATION UK (NORTHAMPTON) participant 51˙187.00

Map

 Project objective

TUDCA-ALS will focus on amyotrophic lateral sclerosis (ALS) a rare neurodegenerative disorder, that affects motor neurons in the brain, brainstem and spinal cord, resulting in progressive weakness and atrophy of voluntary skeletal muscles. ALS has an estimated prevalence of 5.40 cases per 100.000 population corresponding at about 40.000 patients at European level. Treatments are modestly effective at best, and the majority of patients die within 3-5 years of diagnosis, often from respiratory failure. TUDCA-ALS is based on the results of a successful proof-of-concept trial and has the ambition to develop a novel therapy in patients with ALS, based on administration of tauroursodeoxycholic acid (TUDCA) in addition to riluzole. TUDCA-ALS aims to perform a state-of-art randomized control trial on safety and efficacy of TUDCA in patients with sporadic ALS, without cognitive involvement and to exploit the project results into a novel therapeutic treatment for ALS. The trial primary endpoint is deterioration of function measured with the ALS Functional Rating Scale Revised. The secondary endpoints are: (1) Survival time to invasive ventilation (tracheostomy) or death; (2) changes in quality of life parameters measured by the ALSAQ-40 questionnaire; (3) functional changes measured by Forced Vital Capacity, and the EQ-5D scale. Muscle force will be assessed by the MRC scale and a correlated analysis of function and survival will be performed. Two biomarkers will be measured: neurofilament levels in the CSF and serum and MMP-9 expression in serum. The latter is a possible biomarker of TUDCA efficacy. TUDCA-ALS is grounded on promising phase IIb clinical data and is expected to impact positively on the international research efforts on ALS. TUDCA-ALS aims to obtain concrete benefits for patients with ALS. If the trial will prove successful, the consortium will support the development of this treatment at European level by combining expert knowledge and patient cooperation.

 Deliverables

List of deliverables.
Dissemination and exploitation plan Documents, reports 2020-02-13 12:58:06
Project website Websites, patent fillings, videos etc. 2020-02-13 12:58:06

Take a look to the deliverables list in detail:  detailed list of TUDCA-ALS deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TUDCA-ALS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TUDCA-ALS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More